Pancreatic Cancer in adults: diagnosis and management

Appendix E

Prisma Flow Charts

31 July 2017

Draft for Consultation

Developed by the National Guideline Alliance, hosted by the Royal College of Obstetricians and Gynaecologist
Disclaimer
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright
© National Institute for Health and Care Excellence 2017. All rights reserved
Contents

Appendix E: Prisma Flow Charts ........................................................................................................... 5
  E.1 People with jaundice .......................................................................................................................... 5
  E.2 People without jaundice but with a pancreatic abnormality ............................................................. 6
  E.3 Pancreatic cysts ................................................................................................................................. 7
  E.4 People with inherited high risk of pancreatic cancer ......................................................................... 8
  E.5 Referral to specialist multidisciplinary teams .................................................................................. 9
  E.6 Staging ................................................................................................................................................ 10
  E.7 Psychological support needs ............................................................................................................. 11
  E.8 Pain .................................................................................................................................................. 12
  E.9 Nutritional interventions .................................................................................................................. 13
  E.10 Biliary obstruction .......................................................................................................................... 14
  E.11 Duodenal obstruction ....................................................................................................................... 15
  E.12 Neo-adjuvant treatment ................................................................................................................... 16
  E.13 Resectable and borderline resectable pancreatic cancer ............................................................... 17
  E.14 Adjuvant treatment ......................................................................................................................... 18
  E.15 Follow-up for people with resected pancreatic cancer ..................................................................... 19
  E.16 Management of locally advanced pancreatic cancer ................................................................. 20
  E.17 Management of metastatic pancreatic cancer ................................................................................. 21
Appendix E: Prisma Flow Charts

E.1.2 People with jaundice

Titles and abstracts identified, N= 9404

Full copies retrieved and assessed for eligibility, N= 22

Publications included in review, N= 5

Publications excluded from review, N= 17
( refer to excluded studies list)

Excluded (inc. duplicate), N= 9382
(not relevant population, design, intervention, comparison, outcomes, unable to retrieve)
E.2 People without jaundice but with a pancreatic abnormality

1. Titles and abstracts identified, N= 9404
2. Full copies retrieved and assessed for eligibility, N= 130
   - Publications included in review, N= 21
   - Publications excluded from review, N= 109 (refer to excluded studies list)
3. Excluded (inc. duplicates), N= 9274
   (not relevant population, design, intervention, comparison, outcomes, unable to retrieve)
E.3.1 Pancreatic cysts

Titles and abstracts identified, N= 9404

Full copies retrieved and assessed for eligibility, N= 129

Publications included in review, N= 33
- 31 studies plus 2 systematic reviews

Publications excluded from review, N=96
(refer to excluded studies list)

Excluded (inc. duplicates), N= 9275
(not relevant population, design, intervention, comparison, outcomes, unable to retrieve)
E.4.1 People with inherited high risk of pancreatic cancer

1. Titles and abstracts identified, N= 4203
2. Duplicates excluded, N= 922
3. Full copies retrieved and assessed for eligibility, N= 59
4. Excluded, N= 3222
   (not relevant population, design, intervention, comparison, outcomes, unable to retrieve)
5. Publications included in review, N= 18
6. Publications excluded from review, N= 41
   (refer to excluded studies list)
E.51 Referral to specialist multidisciplinary teams

- Titles and abstracts identified, N= 1730

  - Duplicates excluded, N= 2

  - Full copies retrieved and assessed for eligibility, N= 40

    - Excluded, N= 1688
      (not relevant population, design, intervention, comparison, outcomes, unable to retrieve)

    - Publications included in review, N= 0

    - Publications excluded from review, N= 40
      (refer to excluded studies list)
E.6.1 Staging

- Titles and abstracts identified, N= 9404
  - Full copies retrieved and assessed for eligibility, N= 126
    - Publications included in review, N= 29
    - Publications excluded from review, N= 97 (refer to excluded studies list)
  - Excluded, N= 9278 (not relevant population, design, intervention, comparison, outcomes, unable to retrieve)
E.7 Psychological support needs

- Titles and abstracts identified, N= 3482
  - Duplicates excluded, N= 12
  - Full copies retrieved and assessed for eligibility, N= 67
    - Excluded, N= 3403
      (not relevant population, design, intervention, comparison, outcomes, unable to retrieve)
    - Additional studies identified by GC, N= 2
      - Publications included from search, N= 12
        - Publications excluded from review, N= 55
          (refer to excluded studies list)
  - Publications included in review, N= 14
E.81 Pain

1. Titles and abstracts identified, N=1117

2. Full copies retrieved and assessed for eligibility, N= 36

3. Excluded, N= 1081
   (not relevant population, design, intervention, comparison, outcomes, unable to retrieve)

4. Publications included in review, N= 7
   6 studies plus 1 systematic review

5. Publications excluded from review, N=29
   (refer to excluded studies list)
E.9 Nutritional interventions

Titles and abstracts identified, N= 3392

Full copies retrieved and assessed for eligibility, N= 45

Publications included in review, N= 11

Publications excluded from review, N= 34
(refer to excluded studies list)

Excluded, N= 3347
(not relevant population, design, intervention, comparison, outcomes, unable to retrieve)
### E.10 Biliary obstruction

1. Titles and abstracts identified, N= 2782
2. Duplicates excluded, N= 8
3. Full copies retrieved and assessed for eligibility, N= 201
4. Excluded, N= 2574 (not relevant population, design, intervention, comparison, outcomes, unable to retrieve)
5. Additional studies from reference of full copies, N= 4
6. Publications included from search, N= 18
7. Publications excluded from review, N= 183 (refer to excluded studies list)
8. Publications included in review, N= 22
E.11 Duodenal obstruction

Titles and abstracts identified, N= 2203

Duplicates excluded, N= 10

Full copies retrieved and assessed for eligibility, N= 72

Excluded, N= 2121
(not relevant population, design, intervention, comparison, outcomes, unable to retrieve)

Publications included in review, N= 6
(5 studies plus 1 systematic review)

Publications excluded from review, N= 67
(refer to excluded studies list)
**E.12 Neo-adjuvant treatment**

1. **Titles and abstracts identified, N= 14609**
2. **Full copies retrieved and assessed for eligibility, N= 35**
   - Publications included in review, N= 5
     - 3 studies plus 2 systematic reviews
   - Excluded (inc. duplicates), N=14574
     - (not relevant population, design,
3. **Publications excluded from review, N= 30**
   - (refer to excluded studies list)

© National Institute for Health and Care Excellence 2017. All rights reserved
E.13 Resectable and borderline resectable pancreatic cancer

- Titles and abstracts identified, N= 2249
- Duplicates excluded, N= 61
  - Full copies retrieved and assessed for eligibility, N= 112
    - Publications included in review, N= 11
    - Publications excluded from review, N= 101
      (refer to excluded studies list)
  - Excluded, N= 2076
    (not relevant population, design, intervention, comparison, outcomes, unable to retrieve)
E.14 Adjuvant treatment

1. Titles and abstracts identified, N=14609

2. Full copies retrieved and assessed for eligibility, N=146
   - Excluded (inc. duplicates), N=14463
     (not relevant population, design, intervention, comparison, outcomes, unable to retrieve)

3. Publications included in review, N=17
   - Publications excluded from review, N=129
     (refer to excluded studies list)
E.15 Follow-up for people with resected pancreatic cancer

1. Titles and abstracts identified, N= 2484

2. Duplicates excluded, N= 10

3. Full copies retrieved and assessed for eligibility, N= 38

   - Publications included in review, N= 2
   - Publications excluded from review, N= 36
     (refer to excluded studies list)

4. Excluded, N= 2436
   (not relevant population, design, intervention, comparison, outcomes, unable to retrieve)
E.16 Management of locally advanced pancreatic cancer

1. Titles and abstracts identified, N=14609

2. Full copies retrieved and assessed for eligibility, N=62

3. Excluded (inc. duplicates), N=14547
   (not relevant population, design, intervention, comparison, outcomes, unable)

4. Publications included in review, N=18

5. Publications excluded from review, N=44
   (refer to excluded studies list)
E.17 | Management of metastatic pancreatic cancer

- Titles and abstracts identified, N=14609
  - Full copies retrieved and assessed for eligibility, N=114
    - Excluded (inc. duplicates), N=14495 (not relevant population, design, intervention, comparison, outcomes, unable to retrieve)
  - Publications included in review, N=40
  - Publications excluded from review, N=74 (refer to excluded studies list)